Jul 30, 2025 • Zacks Commentary
NEUTRAL
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Jul 29, 2025 • Motley Fool
SOMEWHAT-BULLISH
Alkermes Q2 Sales Up 14 Percent
Alkermes Plc ( NASDAQ:ALKS ) , a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus Wall Street expectations, with diluted earnings per share ( GAAP ) coming in at $0.52, well above ...
Jul 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Alkermes ( ALKS ) Tops Q2 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 28, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Jul 25, 2025 • Zacks Commentary
NEUTRAL
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Jul 24, 2025 • Zacks Commentary
NEUTRAL
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.